SCHEMBL24768084

SCHEMBL24768084

c1ccc(Cc2ccsc2)nc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ CHRNA7 P36544 2/20 0.43
▸ HRH3 Q9Y5N1 2/20 0.42
▸ HRH1 P35367 1/20 0.41
▸ HRH4 Q9H3N8 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TAAR1 Q96RJ0 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ CYP1A2 P05177 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ LIN28A Q9H9Z2 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29373231 0.76 L3MBTL1 (0.68) L3MBTL1HRH3HRH1HRH4SMN1; SMN2
SCHEMBL64435 0.76 L3MBTL1 (0.68) L3MBTL1HRH3HRH1HRH4SMN1; SMN2
SCHEMBL41191 0.75 L3MBTL1 (0.59) L3MBTL1HRH3HRH1HRH4SMN1; SMN2
SCHEMBL29830938 0.75 L3MBTL1 (0.59) L3MBTL1HRH3HRH1HRH4SMN1; SMN2
SCHEMBL31276017 0.74 L3MBTL1 (0.66) L3MBTL1HRH3HRH1HRH4ALDH1A1
SCHEMBL31236458 0.74 L3MBTL1 (0.66) L3MBTL1HRH3HRH1HRH4SMN1; SMN2
Hydrochloric Acid SCHEMBL31087535 0.74 L3MBTL1 (0.71) L3MBTL1HRH3HRH1HRH4ALDH1A1
Bromide SCHEMBL10759788 0.74 L3MBTL1 (0.66) L3MBTL1HRH3HRH1HRH4SMN1; SMN2
SCHEMBL29985764 0.74 L3MBTL1 (0.66) L3MBTL1HRH3HRH1HRH4SMN1; SMN2
SCHEMBL30021715 0.74 L3MBTL1 (0.66) L3MBTL1HRH3HRH1HRH4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders Smilebiotek Zhuhai Limited (CN) 2024-06-25 — — US disclosed
WO-2023125935-A1 BENZOPYRIDINE DERIVATIVE REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2023-07-06 — — WO disclosed
WO-2022263800-A1 PROCESS JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2022-12-22 — — WO disclosed
CN-109134173-B Simple method for synthesizing heterocyclic aryl ketone compound 河南师范大学 2021-03-16 — — CN disclosed
CN-109134173-A The method of easy synthesizing heterocyclic aryl ketones compounds 河南师范大学 2019-01-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders MB, MYOC, PDE6A L3MBTL1 1776/4885CHRNA7 2983/4885HRH3 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback